中华皮肤科杂志 ›› 2026, Vol. 59 ›› Issue (4): 291-303.doi: 10.35541/cjd.20250433
中华医学会皮肤性病学分会儿童学组 中国康复医学会皮肤病康复专业委员会儿童皮肤病学组 中国医师协会皮肤科医师分会儿童皮肤病学组 中国中药协会儿童健康与药物研究专业委员会外治疗法学组 中国医师协会儿科分会皮肤病学组
收稿日期:2025-08-11
修回日期:2026-03-05
发布日期:2026-04-03
通讯作者:
王华;马琳
E-mail: huawang@hospital.cqmu.edu.cn; bch_maleen@ aliyun.com
基金资助:Group on Children, Chinese Society of Dermatology; Pediatric Dermatology Group, Chinese Association of Rehabilitation Dermatology; Pediatric Dermatology Group, China Dermatologist Association; External Therapy Group, Professional Committee for Children's Health and Drug Research, China Association of Traditional Chinese Medicine; Dermatology Group, China Pediatrician Association
Received:2025-08-11
Revised:2026-03-05
Published:2026-04-03
Contact:
Wang Hua; Ma Lin
E-mail: huawang@hospital.cqmu.edu.cn; bch_maleen@ aliyun.com
Supported by:摘要: 【摘要】 斑秃是T细胞介导的自身免疫性非瘢痕性脱发,以毛囊免疫豁免的破坏为核心机制,继而诱发CD8? T细胞介导的自身免疫反应。涉及Th1/Th2/Th17/Treg等多种炎症通路,遗传易感性也发挥一定作用。儿童斑秃具有显著异质性,发病年龄越小(尤其 < 6岁),脱发严重度和复发率越高,对患儿及家庭的生活质量的影响越显著。儿童斑秃需要与先天性和其他后天性儿童脱发性疾病相鉴别。目前儿童斑秃的治疗存在年龄限制及高级别循证医学证据不足的挑战,需根据年龄、疾病分期及严重程度进行分层管理。本共识综合国内外最新诊疗指南及临床研究证据,通过德尔菲法遴选出临床关键问题,组织专家组进行系统论证,形成涵盖临床分型、诊断路径、评估工具及治疗策略的推荐意见,以推进我国儿童斑秃规范化诊疗,并为临床实践提供指导。
中华医学会皮肤性病学分会儿童学组 中国康复医学会皮肤病康复专业委员会儿童皮肤病学组 中国医师协会皮肤科医师分会儿童皮肤病学组 中国中药协会儿童健康与药物研究专业委员会外治疗法学组 中国医师协会儿科分会皮肤病学组 . 中国儿童斑秃诊断和治疗专家共识(2026版)[J]. 中华皮肤科杂志, 2026,59(4):291-303. doi:10.35541/cjd.20250433
Group on Children, Chinese Society of Dermatology, Pediatric Dermatology Group, Chinese Association of Rehabilitation Dermatology, Pediatric Dermatology Group, China Dermatologist Association, External Therapy Group, Professional Committee for Children's Health and Drug Research, China Association of Traditional Chinese Medicine, Dermatology Group, China Pediatrician Association. Expert consensus on the diagnosis and treatment of pediatric alopecia areata in China (2026 edition)[J]. Chinese Journal of Dermatology, 2026, 59(4): 291-303.doi:10.35541/cjd.20250433
| [1] | Gilhar A, Etzioni A, Paus R. Alopecia areata[J]. N Engl J Med, 2012,366(16):1515⁃1525. DOI: 10.1056/NEJMra1103442. |
| [2] | Suchonwanit P, Kositkuljorn C, Pomsoong C. Alopecia areata: an autoimmune disease of multiple players[J]. Immunotargets Ther, 2021,10:299⁃312. DOI: 10.2147/ITT.S266409. |
| [3] | Adhanom R, Ansbro B, Castelo‐Soccio L. Epidemiology of pediatric alopecia areata[J]. Pediatr Dermatol, 2025,42 Suppl 1:12⁃23. DOI: 10.1111/pde.15803. |
| [4] | Franz A, Constantinou A, Hillmann K, et al. Quality of life, psychosocial difficulties and bullying in paediatric patients with alopecia areata: a European cross⁃sectional study[J]. Br J Dermatol, 2025,193(6):1165⁃1173. DOI: 10.1093/bjd/ljaf318. |
| [5] | Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction⁃GRADE evidence profiles and summary of findings tables[J]. J Clin Epidemiol, 2011,64(4):383⁃394. DOI: 10. 1016/j.jclinepi.2010.04.026. |
| [6] | Gandhi V, Baruah MC, Bhattacharaya SN. Nail changes in alopecia areata: incidence and pattern[J]. Indian J Dermatol Venereol Leprol, 2003,69(2):114⁃115. |
| [7] | 刘元香, 孙玉娟, 张霞, 等. 儿童斑秃304例临床回顾性分析[J]. 实用皮肤病学杂志, 2015,(5):354⁃356. DOI: 10.11786/sypfbxzz.1674⁃1293.20150511. |
| [8] | 中华医学会皮肤性病学分会毛发学组. 中国斑秃诊疗指南(2019)[J]. 临床皮肤科杂志, 2020,49(2):69⁃72. DOI: 10. 16761/j.cnki.1000⁃4963.2020.02.002. |
| [9] | Zhou C, Li X, Wang C, et al. Alopecia areata: an update on etiopathogenesis, diagnosis, and management[J]. Clin Rev Allergy Immunol, 2021,61(3):403⁃423. DOI: 10.1007/s12016⁃021⁃08883⁃0. |
| [10] | Tosti A, Bellavista S, Iorizzo M. Alopecia areata: a long term follow⁃up study of 191 patients[J]. J Am Acad Dermatol, 2006,55(3):438⁃441. DOI: 10.1016/j.jaad.2006.05.008. |
| [11] | Lyakhovitsky A, Aronovich A, Gilboa S, et al. Alopecia areata: a long⁃term follow⁃up study of 104 patients[J]. J Eur Acad Dermatol Venereol, 2019,33(8):1602⁃1609. DOI: 10.1111/jdv. 15582. |
| [12] | Fatani M, Alkhalifah A, Alruwaili A, et al. Diagnosis and management of alopecia areata: a Saudi expert consensus statement (2023)[J]. Dermatol Ther (Heidelb), 2023,13(10):2129⁃2151. DOI: 10.1007/s13555⁃023⁃00991⁃3. |
| [13] | Xu L, Liu KX, Senna MM. A practical approach to the diagnosis and management of hair loss in children and adolescents[J]. Front Med (Lausanne), 2017,4:112. DOI: 10. 3389/fmed.2017. 00112. |
| [14] | Spano F, Donovan JC. Alopecia areata: part 1: pathogenesis, diagnosis, and prognosis[J]. Can Fam Physician, 2015,61(9):751⁃755. |
| [15] | Olsen EA, Roberts J, Sperling L, et al. Objective outcome measures: collecting meaningful data on alopecia areata[J]. J Am Acad Dermatol, 2018,79(3):470⁃478. DOI: 10.1016/j.jaad.2017.10.048. |
| [16] | Meah N, Wall D, York K, et al. The Alopecia Areata Consensus of Experts (ACE) study partⅡ: results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata[J]. J Am Acad Dermatol, 2021,84(6):1594⁃1601. DOI: 10.1016/j.jaad.2020.09.028. |
| [17] | Huang Y, Jee E, Kim M, et al. Familial patterns of alopecia areata: A systematic review and meta⁃analysis[J]. J Autoimmun, 2025,151:103378. DOI: 10.1016/j.jaut.2025.103378. |
| [18] | Conic RZ, Tamashunas NL, Damiani G, et al. Comorbidities in pediatric alopecia areata[J]. J Eur Acad Dermatol Venereol, 2020,34(12):2898⁃2901. DOI: 10.1111/jdv.16727. |
| [19] | Wohlmuth⁃Wieser I, Osei JS, Norris D, et al. Childhood alopecia areata⁃data from the National Alopecia Areata Registry[J]. Pediatr Dermatol, 2018,35(2):164⁃169. DOI: 10.1111/pde.13387. |
| [20] | Choi JW, Kim YH, Kwak H, et al. Impact of pediatric alopecia areata on quality of life of patients and their family members: a nationwide multicenter questionnaire study[J]. Ann Dermatol, 2022,34(4):237⁃244. DOI: 10.5021/ad.21.202. |
| [21] | Aryanian Z, Najafi M, Ansari M, et al. Trichoscopic findings in children and adults with alopecia areata: a comparative study[J]. J Cosmet Dermatol, 2024,23(8):2736⁃2742. DOI: 10.1111/jocd.16319. |
| [22] | Raheem A, Al⁃Dhalimi M. Comparative study of trichoscopic features of alopecia areata between adults and children and between different body parts (scalp, beard, eyebrow, and moustache)[J]. Indian J Dermatol, 2024,69(4):285⁃291. DOI: 10.4103/ijd.ijd_346_23. |
| [23] | Al⁃Dhubaibi MS, Alsenaid A, Alhetheli G, et al. Trichoscopy pattern in alopecia areata: a systematic review and meta⁃analysis[J]. Skin Res Technol, 2023,29(6):e13378. DOI: 10.1111/srt.13378. |
| [24] | Al Chalabi QS, Fathi HB, Al Mallah MN. Alopecia areata: dermatoscopic differences between pediatric and adult patients[J]. J Pakistan Assoc Dermatol, 2023,33(4): 1404⁃1411. |
| [25] | 赵莹, 蔡泽明, 巩毓刚, 等. 斑秃皮损的皮肤镜影像及其与临床病理的关系[J]. 中华皮肤科杂志, 2011,44(1):30⁃34. DOI: 10.3760/cma.j.issn.0412⁃4030.2011.01.011. |
| [26] | Peckham SJ, Sloan SB, Elston DM. Histologic features of alopecia areata other than peribulbar lymphocytic infiltrates[J]. J Am Acad Dermatol, 2011,65(3):615⁃620. DOI: 10.1016/j.jaad.2011.02.017. |
| [27] | Li SF, Zhang XT, Qi SL, et al. Allergy to dust mites may contribute to early onset and severity of alopecia areata[J]. Clin Exp Dermatol, 2015,40(2):171⁃176. DOI: 10.1111/ced.12471. |
| [28] | Conteduca G, Rossi A, Megiorni F, et al. Single nucleotide polymorphisms in the promoter regions of Foxp3 and ICOSLG genes are associated with alopecia areata[J]. Clin Exp Med, 2014,14(1):91⁃97. DOI: 10.1007/s10238⁃012⁃0224⁃3. |
| [29] | Yip L, Horev L, Sinclair R, et al. Atrichia with papular lesions: a report of three novel human hairless gene mutations and a revision of diagnostic criteria[J]. Acta Derm Venereol, 2008,88(4):346⁃349. DOI: 10.2340/00015555⁃0466. |
| [30] | Alves R, Grimalt R. Hair loss in children[J]. Curr Probl Dermatol, 2015,47:55⁃66. DOI: 10.1159/000369405. |
| [31] | Patel D, Li P, Bauer AJ, et al. Screening guidelines for thyroid function in children with alopecia areata[J]. JAMA Dermatol, 2017,153(12):1307⁃1310. DOI: 10.1001/jamadermatol.2017. 3694. |
| [32] | Nanda A, Al⁃Fouzan AS, Al⁃Hasawi F. Alopecia areata in children: a clinical profile[J]. Pediatr Dermatol, 2002,19(6):482⁃485. DOI: 10.1046/j.1525⁃1470.2002.00215.x. |
| [33] | Rossi A, Muscianese M, Piraccini BM, et al. Italian guidelines in diagnosis and treatment of alopecia areata[J]. G Ital Dermatol Venereol, 2019,154(6):609⁃623. DOI: 10.23736/S0392⁃0488. 19.06458⁃7. |
| [34] | Wyrwich KW, Kitchen H, Knight S, et al. The alopecia areata investigator global assessment scale: a measure for evaluating clinically meaningful success in clinical trials[J]. Br J Dermatol, 2020,183(4):702⁃709. DOI: 10.1111/bjd.18883. |
| [35] | Bernardis E, Nukpezah J, Li P, et al. Pediatric severity of alopecia tool[J]. Pediatr Dermatol, 2018,35(1):e68⁃e69. DOI: 10.1111/pde.13327. |
| [36] | King BA, Mesinkovska NA, Craiglow B, et al. Development of the alopecia areata scale for clinical use: results of an academic⁃industry collaborative effort[J]. J Am Acad Dermatol, 2022,86(2):359⁃364. DOI: 10.1016/j.jaad.2021.08.043. |
| [37] | ASAMI Consensus Survey Study Group, Moussa A, Bennett M, et al. The alopecia areata severity and morbidity index (ASAMI) study: results from a global expert consensus exercise on determinants of alopecia areata severity[J]. JAMA Dermatol, 2024,160(3):341⁃350. DOI: 10.1001/jamadermatol. 2023.5869. |
| [38] | Wyrwich KW, Kitchen H, Knight S, et al. Development of clinician⁃reported outcome (ClinRO) and patient⁃reported outcome (PRO) measures for eyebrow, eyelash and nail assessment in alopecia areata[J]. Am J Clin Dermatol, 2020,21(5):725⁃732. DOI: 10.1007/s40257⁃020⁃00545⁃9. |
| [39] | Olsen EA, Hordinsky MK, Price VH, et al. Alopecia areata investigational assessment guidelines⁃⁃Part II. National Alopecia Areata Foundation[J]. J Am Acad Dermatol, 2004,51(3):440⁃447. DOI: 10.1016/j.jaad.2003.09.032. |
| [40] | Olsen EA, Canfield D. SALTⅡ: a new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss[J]. J Am Acad Dermatol, 2016,75(6):1268⁃1270. DOI: 10. 1016/j.jaad.2016.08.042. |
| [41] | Wambier CG, King BA. Rule of thumb: a simple tool to estimate 1% scalp surface area[J]. J Am Acad Dermatol, 2019,81(2):630⁃631. DOI: 10.1016/j.jaad.2019.01.022. |
| [42] | Ito T, Kamei K, Yuasa A, et al. Health⁃related quality of life in patients with alopecia areata: results of a Japanese survey with norm⁃based comparisons[J]. J Dermatol, 2022,49(6):584⁃593. DOI: 10.1111/1346⁃8138.16364. |
| [43] | Lenane P, Macarthur C, Parkin PC, et al. Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in children: a randomized clinical trial[J]. JAMA Dermatol, 2014,150(1):47⁃50. DOI: 10.1001/jamadermatol.2013.5764. |
| [44] | Lee YY, Lim HH, Son S, et al. Efficacy and safety of topical corticosteroid treatment under occlusion for severe alopecia areata in children: a single⁃centre retrospective analysis[J]. Clin Exp Dermatol, 2024,49(10):1125⁃1130. DOI: 10.1093/ced/llae085. |
| [45] | 曹慧, 杨雨清, 李水凤, 等. 强效糖皮质激素局部封包法治疗儿童斑秃疗效观察[J]. 临床皮肤科杂志, 2015,44(10):647⁃651. |
| [46] | Porter D, Burton JL. A comparison of intra⁃lesional triamcinolone hexacetonide and triamcinolone acetonide in alopecia areata[J]. Br J Dermatol, 1971,85(3):272⁃273. DOI: 10.1111/j.1365⁃2133.1971.tb07230.x. |
| [47] | Wang E, Lee JS, Tang M. Current treatment strategies in pediatric alopecia areata[J]. Indian J Dermatol, 2012,57(6):459⁃465. DOI: 10.4103/0019⁃5154.103066. |
| [48] | Chang KH, Rojhirunsakool S, Goldberg LJ. Treatment of severe alopecia areata with intralesional steroid injections[J]. J Drugs Dermatol, 2009,8(10):909⁃912. |
| [49] | Barton VR, Toussi A, Awasthi S, et al. Treatment of pediatric alopecia areata: a systematic review[J]. J Am Acad Dermatol, 2022,86(6):1318⁃1334. DOI: 10.1016/j.jaad.2021.04.077. |
| [50] | Tembunde Y, Kindred C. Ruxolitinib 1.5% topical cream for the treatment of pediatric alopecia areata[J]. J Drugs Dermatol, 2024,23(5):378⁃379. DOI: 10.36849/JDD.7782. |
| [51] | Bayart CB, DeNiro KL, Brichta L, et al. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata[J]. J Am Acad Dermatol, 2017,77(1):167⁃170. DOI: 10.1016/j.jaad.2017. 03.024. |
| [52] | 张帆, 糜自豪, 孙勇虎. 外用磷酸二酯酶4抑制剂软膏治疗斑秃一例附文献复习[J]. 中国麻风皮肤病杂志, 2022,38(4):217⁃219. DOI: 10.12144/zgmfskin202204217. |
| [53] | Ramos PM, Anzai A, Duque⁃Estrada B, et al. Consensus on the treatment of alopecia areata ⁃ Brazilian Society of Dermatology[J]. An Bras Dermatol, 2020,95 Suppl 1:39⁃52. DOI: 10.1016/j.abd.2020.05.006. |
| [54] | Kalil L, Welch D, Heath CR, et al. Systemic therapies for pediatric alopecia areata[J]. Pediatr Dermatol, 2025,42 Suppl 1:36⁃42. DOI: 10.1111/pde.15822. |
| [55] | Mahajan R, Daroach M, Handa S, et al. Randomized controlled trial to compare the effectiveness and safety of low dose dexamethasone oral mini⁃pulse versus diphenylcyclopropenone contact sensitisation in severe pediatric alopecia areata[J]. Dermatol Ther, 2022,35(11):e15810. DOI: 10.1111/dth.15810. |
| [56] | Lalosevic J, Gajic⁃Veljic M, Bonaci⁃Nikolic B, et al. Combined oral pulse and topical corticosteroid therapy for severe alopecia areata in children: a long⁃term follow⁃up study[J]. Dermatol Ther, 2015,28(5):309⁃317. DOI: 10.1111/dth.12255. |
| [57] | Hordinsky M, Hebert AA, Gooderham M, et al. Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double⁃blind, placebo⁃controlled trial[J]. Pediatr Dermatol, 2023,40(6):1003⁃1009. DOI: 10.1111/pde.15378. |
| [58] | Gonzalez ME, Browning J, Smith S, et al. A phase 1, open⁃label study of the pharmacokinetics of ritlecitinib in children aged 6-12 years with alopecia areata[J]. Pediatr Dermatol, 2025,42(4):742⁃746. DOI: 10.1111/pde.15895. |
| [59] | Huang J, Jian J, Li M, et al. Effectiveness and tolerability of ritlecitinib in children with alopecia areata: a case series[J]. J Am Acad Dermatol, 2025,92(6):1395⁃1397. DOI: 10.1016/j.jaad.2025.01.090. |
| [60] | Wang X, Liu Y, Sun Y, et al. Ritlecitinib for severe alopecia areata in children under 12 years: a retrospective review of 18 cases[J]. J Am Acad Dermatol, 2026,94(1):280⁃282. DOI: 10.1016/j.jaad.2025.09.008. |
| [61] | King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata[J]. N Engl J Med, 2022,386(18):1687⁃1699. DOI: 10.1056/NEJMoa2110343. |
| [62] | Wan M, Zhang M, Song X, et al. Tolerability and efficacy of unorthodox dosing regimens of tofacitinib and baricitinib in pediatric patients with moderate to severe alopecia areata[J]. J Am Acad Dermatol, 2025,DOI: 10.1016/j.jaad.2025.10.030. |
| [63] | Asfour L, Bokhari L, Bhoyrul B, et al. Treatment of moderate⁃to⁃severe alopecia areata in pre⁃adolescent children with baricitinib[J]. Br J Dermatol, 2023,189(2):248⁃250. DOI: 10.1093/bjd/ljad118. |
| [64] | Behrangi E, Barough MS, Khoramdad M, et al. Efficacy and safety of tofacitinib for treatment of alopecia areata in children: a systematic review and meta⁃analysis[J]. J Cosmet Dermatol, 2022,21(12):6644⁃6652. DOI: 10.1111/jocd.15425. |
| [65] | 刘元香, 梁源, 赵欣荣, 等. JAK抑制剂治疗儿童重症斑秃5例[J]. 中华皮肤科杂志, 2023,56(9):849⁃852. DOI: 10.35541/cjd.20220317. |
| [66] | Picone V, Nappa P, Napolitano M, et al. Upadacitinib for the management of severe alopecia areata in adolescent patients: a single⁃centre retrospective study[J]. Clin Exp Dermatol, 2024,50(1):153⁃155. DOI: 10.1093/ced/llae309. |
| [67] | Kołcz K, Żychowska M, Sawińska E, et al. Alopecia universalis in an adolescent successfully treated with upadacitinib⁃a case report and review of the literature on the use of JAK inhibitors in pediatric alopecia areata[J]. Dermatol Ther (Heidelb), 2023,13(3):843⁃856. DOI: 10.1007/s13555⁃023⁃00889⁃0. |
| [68] | Huang J, Jian J, Li M, et al. Sustaining treatment response in alopecia areata through tofacitinib dose tapering: a single⁃center retrospective study[J/OL]. J Am Acad Dermatol, 2025(2025⁃12⁃08)[2026⁃03⁃16]. https://www.sciencedirect.com/science/article/pii/S0190962225033523?via%3Dihub. DOI: 10.1016/j.jaad.2025.12.020. [published online ahead of print]. |
| [69] | Metko D, Mehta S, Sibbald C. Dupilumab for the treatment of alopecia areata in pediatric patients with atopic dermatitis: a scoping review[J]. Pediatr Dermatol, 2024,41(6):1123⁃1126. DOI: 10.1111/pde.15691. |
| [70] | Li M, Xiang L, Li Y. Efficacy and safety of compound glycyrrhizin in patients with alopecia areata: a systematic review and meta⁃analysis[J]. Ann Med, 2025,57(1):2491659. DOI: 10.1080/07853890.2025.2491659. |
| [71] | Yang D, Zheng J, Zhang Y, et al. Total glucosides of paeony capsule plus compound glycyrrhizin tablets for the treatment of severe alopecia areata in children: a randomized controlled trial[J]. Evid Based Complement Alternat Med, 2013,2013:378219. DOI: 10.1155/2013/378219. |
| [72] | Cho S, Choi MJ, Zheng Z, et al. Clinical effects of non⁃ablative and ablative fractional lasers on various hair disorders: a case series of 17 patients[J]. J Cosmet Laser Ther, 2013,15(2):74⁃79. DOI: 10.3109/14764172.2013.764436. |
| [73] | Behrangi E, Roohaninasab M, Sadeghzadeh⁃Bazargan A, et al. A systematic review on the treatment of pediatric severe alopecia areata by topical immunotherapy or Anthralin (contact sensitization) or low⁃level light/laser therapy (LLLT): focus on efficacy, safety, treatment duration, recurrence, and follow⁃up based on clinical studies[J]. J Cosmet Dermatol, 2022,21(7):2727⁃2741. DOI: 10.1111/jocd.14480. |
| [74] | Pei D, Chen L, Yao Y, et al. Microneedling combined with compound betamethasone in treatment of severe alopecia areata: a case report[J]. Front Immunol, 2022,13:939077. DOI: 10. 3389/fimmu.2022.939077. |
| [75] | 国家卫生健康委员会毛发质控项目专家委员会, 国家中西医结合医学中心毛发专病医联体, 中国整形美容协会中医美容分会, 等. 斑秃中西医结合诊疗专家共识(2024版)[J]. 中国中西医结合皮肤性病学杂志, 2025,24(3):263⁃273. DOI: 10.3969/j.issn.1672⁃0709.2025.03.021. |
| [76] | 苏婷, 钟江. 儿童斑秃的中西医治疗进展[J]. 广西中医药大学学报, 2017,20(4):63⁃65. DOI: 10.3969/j.issn.2095⁃4441. 2017.04.026. |
| [77] | 袁翠英. 中医药治疗斑秃102例[J]. 中华皮肤科杂志, 2004,37(2):113. |
| [78] | 叶有骏, 王莉, 张婷, 等. 中医药治疗斑秃研究进展[J]. 江西中医药大学学报, 2024,36(5):104⁃107. DOI: 10.20140/j.2095⁃7785.2024.05.27. |
| [79] | Aşkın Ö, Koyuncu Z, Serdaroğlu S. Association of alopecia with self⁃esteem in children and adolescents[J]. Int J Adolesc Med Health, 2022,34(5):315⁃318. DOI: 10.1515/ijamh⁃2020⁃0100. |
| [80] | Savaş Erdoğan S, Falay Gür T, Doğan B. Anxiety and depression in pediatric patients with vitiligo and alopecia areata and their parents: a cross⁃sectional controlled study[J]. J Cosmet Dermatol, 2021,20(7):2232⁃2239. DOI: 10.1111/jocd.13807. |
| [81] | Toussi A, Barton VR, Le ST, et al. Psychosocial and psychiatric comorbidities and health⁃related quality of life in alopecia areata: a systematic review[J]. J Am Acad Dermatol, 2021,85(1):162⁃175. DOI: 10.1016/j.jaad.2020.06.047. |
| [1] | 中国医学装备协会皮肤病与皮肤美容分会 中国临床肿瘤学会患者教育专家委员会. [开放获取] 肿瘤治疗相关皮肤不良反应多学科管理中国专家共识(2026版)[J]. 中华皮肤科杂志, 2026, 59(4): 304-319. |
| [2] | 陈雪 张建中. [开放获取] 慢性手部湿疹:流行病学、疾病负担、发病机制及管理[J]. 中华皮肤科杂志, 2026, 59(4): 327-332. |
| [3] | 薛舒月 李婷婷 康晓静. 脂质代谢在皮肤恶性肿瘤发生发展及诊疗中的研究进展 [J]. 中华皮肤科杂志, 2026, 59(4): 379-382. |
| [4] | 王碧伟 李赛 乐文静 赵诗轩 陈雅丽 赵园园 甘璐 朱小凤 苏晓红. 磁微粒化学发光法检测梅毒特异性抗体的复检范围探讨研究[J]. 中华皮肤科杂志, 2026, 59(4): 370-373. |
| [5] | 黄祺甯 马银超 王子元 鲁锡霖 齐映婷 刘孜妍 门月华 初明 张春雷. 黄连素软膏对特应性皮炎样小鼠皮肤炎症及菌群的影响作用[J]. 中华皮肤科杂志, 2026, 59(4): 353-360. |
| [6] | 中国整形美容协会皮肤美容分会 中国非公立医疗机构协会皮肤专业委员会. [开放获取] 医用重组人源化胶原蛋白在面部年轻化中的应用专家建议(2026版)[J]. 中华皮肤科杂志, 2026, 59(4): 320-326. |
| [7] | 曾莞欣 文翔. 增生性瘢痕的光电治疗进展[J]. 中华皮肤科杂志, 2026, 59(3): 269-273. |
| [8] | 范慧琳 赵慧敏 彭依然 汪犇 黄莹雪 赵志祥 唐言 简丹. 低能量CO2点阵激光治疗玫瑰痤疮难治性持续性红斑的回顾性研究[J]. 中华皮肤科杂志, 2026, 59(3): 218-223. |
| [9] | 朱芸 王建才 杨明 顾菲 张洪丽 高莹. 755 nm皮秒激光治疗儿童咖啡牛奶斑的疗效及影响因素分析[J]. 中华皮肤科杂志, 2026, 59(3): 224-229. |
| [10] | 夏志宽 葛格. [开放获取] 白癜风激光治疗临床应用与展望[J]. 中华皮肤科杂志, 2026, 59(3): 213-217. |
| [11] | 中华医学会皮肤性病学分会银屑病专业委员会. 伴共病的银屑病管理共识(2026版)[J]. 中华皮肤科杂志, 2026, 59(3): 193-207. |
| [12] | “Chinese expert consensus on the clinical application of photobiomodulation therapy in dermatology ”解读专家组 中华医学会皮肤性病学分会激光学组. [开放获取] 2025版光生物调节疗法在皮肤科的临床应用中国专家共识要点解读[J]. 中华皮肤科杂志, 2026, 59(3): 208-212. |
| [13] | 王钧程 刘洁. [开放获取] 人工智能在银屑病临床诊疗与患者管理中的应用进展[J]. 中华皮肤科杂志, 2026, 0(3): 20240061-e20240061. |
| [14] | 王丽 王千秋 张瑞丽. 隐性梅毒研究进展[J]. 中华皮肤科杂志, 2026, 59(3): 286-289. |
| [15] | 卢红铮 何瑞 杨思燕 马琳 张斌. 外用噻吗洛尔联合脉冲染料激光治疗儿童丛状血管瘤1例[J]. 中华皮肤科杂志, 2026, 59(3): 253-254. |
|